KYMR on Nasdaq
Kymera Therapeutics
Biopharmaceutical company based in Watertown1
In its 2026 annual report the company says: “We are a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of innovative, highly differentiated oral medicines that address significant health problems and meaningfully improve patients’ lives. We are committed to advancing novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies.”5 Its shares trade on Nasdaq under the symbol KYMR.1
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with SANGAMO THERAPEUTICS, INC, Voyager Therapeutics (United States) or Editas Medicine, or pick any stock.
- TickerKYMR on Nasdaq1
- Industrypharmaceutical industry1
- HeadquartersWatertown1
- Websitewww.kymeratx.com
- Incorporated inDE3
- Business address500 North Beacon Street, 4Th Floor, Watertown, Ma 024723
- Filer categoryLarge accelerated filer3
See how the biggest companies compare on our leaderboards
We are a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of innovative, highly differentiated oral medicines that address significant health problems and meaningfully improve patients’ lives. We are committed to advancing novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Our approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner.5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-891.1%Operating margin6
-794.0%Net margin6
-16.7%Revenue growth, 20256
-19.7%Return on equity6
-$234.3MFree cash flow6
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue11¢$39.2M
- Research and development89¢$316.6M
Out of $39.2M in revenue.6 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Collaboration revenue | $39.2M | $47.1M | $78.6M |
| Research and development | $316.6M | $240.2M | $189.1M |
| General and administrative | $68.2M | $63.5M | $55.0M |
| Impairment of long-lived assets | $3.9M | $4.9M | $0 |
| Total operating expenses | $388.6M | $308.7M | $244.1M |
| Loss from operations | -$349.4M | -$261.6M | -$165.5M |
| Interest and other income | $38.4M | $38.0M | $18.8M |
| Interest and other expense | -$370.0K | -$249.0K | -$196.0K |
| Total other income | $38.0M | $37.8M | $18.6M |
| Net loss | -$311.4M | -$223.9M | -$147.0M |
| Unrealized gain (loss) on marketable securities | $3.3M | -$933.0K | $4.4M |
| Total comprehensive loss | -$308.1M | -$224.8M | -$142.6M |
| Net loss attributable to common stockholders | -$311.4M | -$223.9M | -$147.0M |
| Net loss per share, basic | -$3.69 | -$2.98 | -$2.52 |
| Net loss per share, diluted | -$3.69 | -$2.98 | -$2.52 |
| Total weighted average common stock outstanding, basic and diluted | 84.5M shares | 75.0M shares | 58.4M shares |
| Total weighted average common stock outstanding, basic and diluted | 84.5M shares | 75.0M shares | 58.4M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $357.0M | $120.3M | $110.0M | |
| Marketable securities (Note 4) | $491.3M | $368.5M | ||
| Prepaid expenses and other current assets | $22.9M | $21.5M | ||
| Total current assets | $871.2M | $510.3M | ||
| Marketable securities, non-current (Note 4) | $771.2M | $362.2M | ||
| Property and equipment, net (Note 6) | $43.2M | $50.5M | ||
| Right-of-use assets, operating leases | $42.4M | $47.4M | ||
| Other non-current assets | $9.1M | $1.9M | ||
| Restricted cash | $5.8M | $5.8M | ||
| Total assets | $1.7B | $978.0M | ||
| Accounts payable | $4.0M | $6.0M | ||
| Accrued expenses (Note 8) | $42.3M | $34.9M | ||
| Deferred revenue | $22.9M | $13.6M | ||
| Operating lease liabilities | $11.9M | $11.6M | ||
| Finance lease liabilities | $1.8M | $1.5M | ||
| Other current liabilities | $242.0K | $223.0K | ||
| Total current liabilities | $83.2M | $67.8M | ||
| Deferred revenue, net of current portion | $11.4M | $0 | ||
| Operating lease liabilities, net of current portion | $67.0M | $72.4M | ||
| Finance lease liabilities, net of current portion | $1.5M | $2.2M | ||
| Total liabilities | $163.1M | $142.4M | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2025 and 2024; 0 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $0 | $0 | ||
| Common stock, $0.0001 par value; 150,000,000 shares authorized at December 31, 2025 and 2024, 81,323,532 and 64,890,193 shares issued and outstanding at December 31, 2025 and 2024, respectively | $8.0K | $7.0K | ||
| Additional paid-in capital | $2.6B | $1.6B | ||
| Accumulated deficit | -$1.1B | -$754.6M | ||
| Accumulated other comprehensive income (loss) | $1.8M | -$1.5M | ||
| Total stockholders' equity | $1.6B | $835.6M | $395.0M | $490.2M |
| Total liabilities and stockholders' equity | $1.7B | $978.0M | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, authorized | 150.0M shares | 150.0M shares | ||
| Common stock, issued | 81.3M shares | 64.9M shares | ||
| Common Stock, outstanding | 81.3M shares | 64.9M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $357.0M | $120.3M | $110.0M | |
| Marketable securities (Note 4) | $491.3M | $368.5M | ||
| Prepaid expenses and other current assets | $22.9M | $21.5M | ||
| Total current assets | $871.2M | $510.3M | ||
| Marketable securities, non-current (Note 4) | $771.2M | $362.2M | ||
| Property and equipment, net (Note 6) | $43.2M | $50.5M | ||
| Right-of-use assets, operating leases | $42.4M | $47.4M | ||
| Other non-current assets | $9.1M | $1.9M | ||
| Restricted cash | $5.8M | $5.8M | ||
| Total assets | $1.7B | $978.0M | ||
| Accounts payable | $4.0M | $6.0M | ||
| Accrued expenses (Note 8) | $42.3M | $34.9M | ||
| Deferred revenue | $22.9M | $13.6M | ||
| Operating lease liabilities | $11.9M | $11.6M | ||
| Finance lease liabilities | $1.8M | $1.5M | ||
| Other current liabilities | $242.0K | $223.0K | ||
| Total current liabilities | $83.2M | $67.8M | ||
| Deferred revenue, net of current portion | $11.4M | $0 | ||
| Operating lease liabilities, net of current portion | $67.0M | $72.4M | ||
| Finance lease liabilities, net of current portion | $1.5M | $2.2M | ||
| Total liabilities | $163.1M | $142.4M | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2025 and 2024; 0 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $0 | $0 | ||
| Common stock, $0.0001 par value; 150,000,000 shares authorized at December 31, 2025 and 2024, 81,323,532 and 64,890,193 shares issued and outstanding at December 31, 2025 and 2024, respectively | $8.0K | $7.0K | ||
| Additional paid-in capital | $2.6B | $1.6B | ||
| Accumulated deficit | -$1.1B | -$754.6M | ||
| Accumulated other comprehensive income (loss) | $1.8M | -$1.5M | ||
| Total stockholders' equity | $1.6B | $835.6M | $395.0M | $490.2M |
| Total liabilities and stockholders' equity | $1.7B | $978.0M | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, authorized | 150.0M shares | 150.0M shares | ||
| Common stock, issued | 81.3M shares | 64.9M shares | ||
| Common Stock, outstanding | 81.3M shares | 64.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$311.4M | -$223.9M | -$147.0M |
| Stock-based compensation expense | $59.9M | $55.0M | $43.1M |
| Impairment of long-lived assets | $3.9M | $4.9M | $0 |
| Depreciation and amortization | $8.3M | $7.4M | $3.6M |
| Premiums and discounts on available for sale marketable securities | -$8.9M | -$14.0M | -$5.2M |
| Prepaid expenses and other assets | -$2.4M | -$8.9M | -$2.0M |
| Accounts receivable | $0 | $15.0M | -$15.0M |
| Contract asset | $947.0K | $2.8M | -$1.2M |
| Accounts payable | -$2.0M | -$307.0K | $2.0M |
| Accrued expenses and other current liabilities | $7.4M | $4.2M | $3.2M |
| Deferred revenue | $20.8M | -$41.1M | -$8.6M |
| Operating lease right-of-use assets | $2.7M | $2.5M | $4.8M |
| Operating lease liabilities | -$5.0M | $1.9M | $18.6M |
| Other non-current assets | -$7.2M | $168.0K | $909.0K |
| Other non-current liabilities | $18.0K | -$310.0K | -$28.0K |
| Net cash used in operating activities | -$232.9M | -$194.5M | -$102.8M |
| Purchase of property and equipment, net | -$1.4M | -$12.8M | -$34.5M |
| Purchase of marketable securities | -$1.0B | -$901.2M | -$189.2M |
| Maturities of marketable securities | $488.0M | $510.0M | $363.5M |
| Net cash provided by (used in) investing activities | -$521.1M | -$404.1M | $139.9M |
| Issuance of common stock and accompanying pre-funded warrants from January 2024 public offering, net of issuance costs of $14.9 million | $0 | $301.4M | $0 |
| Proceeds from issuance of common stock through At-The Market Sales Agreement, net of issuance costs of $1.2 million | $0 | $48.7M | $0 |
| Issuance of common stock and accompanying pre-funded warrants from August 2024 public offering, net of issuance costs of $12.2 million | $0 | $246.5M | $0 |
| Issuance of common stock from December 2025 public offering, net of issuance costs of $36.2 million | $656.2M | $0 | $0 |
| Proceeds from stock option exercises | $61.6M | $11.8M | $2.9M |
| Issuance of common stock and accompanying pre-funded warrants from June 2025 public offering, net of issuance costs of $15.7 million | $272.7M | $0 | $0 |
| Proceeds from employee stock purchase plan | $1.7M | $2.0M | $1.4M |
| Payments on financing leases | -$1.5M | -$1.6M | -$76.0K |
| Net cash provided by financing activities | $990.7M | $608.9M | $4.2M |
| Net increase (decrease) in cash, cash equivalents and restricted cash | $236.8M | $10.3M | $41.3M |
| Right-of-use assets obtained in exchange for operating lease liabilities | $0 | $0 | $48.8M |
| Cash paid for interest | $312.0K | $206.0K | $162.0K |
| Purchases of property and equipment through finance and lease liabilities | $1.0M | $2.7M | $0 |
| Property and equipment purchases included in accounts payable and accrued expenses | $80.0K | $60.0K | $4.0M |
| Issuance of common stock under ATM | $1.2M | $1.2M | $1.2M |
| Private placement, net of issuance costs | $14.9M |
No quarter-by-quarter statement was filed.
Corporate structure
Kymera Therapeutics sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Kymera Therapeutics
- PRICE T ROWE ASSOCIATES INC /MD/ Filed SCHEDULE 13G/A on Kymera Therapeutics, latest Sep 8, 2026 (9 filings since Feb 14, 2022)
- Atlas Venture Fund X, L.P. Filed SCHEDULE 13G/A on Kymera Therapeutics, latest Aug 13, 2026 (5 filings since Feb 11, 2022)
- BIOTECHNOLOGY VALUE FUND L P Filed SCHEDULE 13D/A on Kymera Therapeutics, latest Jun 26, 2026 (6 filings since Jan 31, 2022)
- T. Rowe Price Investment Management, Inc. Filed SCHEDULE 13G on Kymera Therapeutics, latest May 15, 2026
- Wellington Management Company Filed SCHEDULE 13G/A on Kymera Therapeutics, latest May 15, 2026 (9 filings since Feb 4, 2022)
- FMR LLC Filed SCHEDULE 13G/A on Kymera Therapeutics, latest May 6, 2026 (6 filings since Feb 9, 2022)
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on Kymera Therapeutics, latest Mar 27, 2026 (5 filings since Feb 10, 2022)
- BAKER BROS. ADVISORS LP Filed SCHEDULE 13D/A on Kymera Therapeutics, latest Dec 11, 2025 (6 filings since Feb 14, 2023)
- BlackRock Filed SCHEDULE 13G/A on Kymera Therapeutics, latest Jul 17, 2025 (4 filings since Feb 4, 2022)
- Avoro Capital Advisors LLC Filed SC 13G/A on Kymera Therapeutics, latest Nov 14, 2024 (3 filings since Feb 14, 2023)
- State Street Corporation Filed SC 13G/A on Kymera Therapeutics, latest Jan 23, 2024 (2 filings since Feb 8, 2023)
- Vertex Pharmaceuticals Filed SC 13D/A on Kymera Therapeutics, latest Jun 5, 2023
- Kymera Therapeutics Watertown
- Kymera Securities Corporation Subsidiary · Massachusetts, United States
Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Kymera Therapeutics reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $65.3M6 Dec 31, 2025 | $66.5M6 Dec 31, 2024 | −1.8% |
| Accumulated depreciation | $22.1M6 Dec 31, 2025 | $16.1M6 Dec 31, 2024 | +37.7% |
| Property and equipment, net | $43.2M6 Dec 31, 2025 | $50.5M6 Dec 31, 2024 | −14.4% |
| Operating-lease assets (leased space) | $42.4M6 Dec 31, 2025 | $47.4M6 Dec 31, 2024 | −10.7% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $357.0M6 Dec 31, 2025 | $120.3M6 Dec 31, 2024 | +196.9% |
| Marketable securities, current | $491.3M6 Dec 31, 2025 | $368.5M6 Dec 31, 2024 | +33.3% |
| Marketable securities, non-current | $771.2M6 Dec 31, 2025 | $362.2M6 Dec 31, 2024 | +112.9% |
| Debt securities available for sale | $1.3B6 Dec 31, 2025 | $730.6M6 Dec 31, 2024 | +72.8% |
Properties, in its own words
We currently occupy approximately 100,624 square feet of office and laboratory space in Watertown, Massachusetts under a lease that expires in March 2035. We have two options to extend the lease term, each for five additional years at then-market rates. Additionally, we currently lease approximately 34,522 rentable square feet of extra office and laboratory space in Watertown, Massachusetts under a lease that expires in March 2030 that we are not currently occupying. We intend to sublease and are actively marketing the original space to third parties. We believe that our office and laboratory space is sufficient to meet our current needs and that suitable additional space will be available as and when needed on commercially reasonable terms.
Item 2 of the 10-K filed Feb 26, 2026.5
Leadership
Who has led Kymera Therapeutics, and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
2025
- Chief executive officerNello Mainolfi Aug 20, 2020 to now14
- PresidentNello Mainolfi Aug 20, 2020 to Aug 21, 202014
- Chief financial officerBruce N. Jacobs Aug 20, 2020 to now15
- Chief operating officerJeremy G. Chadwick May 22, 2023 to now16
Board members and other officers (23)
- Chief Medical OfficerTerence Rooney Jul 27, 2026 to now17
- Chief Business OfficerNoah Goodman Apr 9, 2025 to now18
- Chief Business OfficerElaine Caughey Jun 21, 2021 to Mar 3, 202319
- Chief Medical OfficerJared Gollob Aug 20, 2020 to now20
- Chief Scientific OfficerRichard Chesworth Aug 20, 2020 to Aug 27, 202121
- Board memberFelix Baker Apr 1, 2024 to now22
- Board memberJulian Baker Apr 1, 2024 to now22
- Board memberL.p. 667 Apr 1, 2024 to now22
- Board memberMark N. Lampert Jan 13, 2023 to now23
- Board memberJohn Maraganore Jan 19, 2022 to now24
- Board memberLeigh Morgan Jul 8, 2022 to Jun 20, 202425
- Board memberVictor Sandor Nov 3, 2022 to now26
- Board memberElena Ridloff Mar 16, 2021 to now27
- Board memberAndrew Hedin Aug 20, 2020 to Aug 21, 202028
- Board memberBruce Booth Aug 20, 2020 to now29
- Board memberGorjan Hrustanovic Aug 20, 2020 to now30
- Board memberJeffrey W. Albers Aug 20, 2020 to now31
- Board memberJoanna Horobin Aug 20, 2020 to Jun 7, 202432
- Board memberNello Mainolfi Aug 20, 2020 to now14
- Board memberSteven Edward Hall Aug 20, 2020 to Jun 17, 202133
- Board memberPamela Esposito Sep 9, 2020 to now34
- General counselBrian Adams Sep 3, 2025 to now35
- General counselEllen Chiniara Jan 4, 2023 to Mar 3, 202536
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- Kymera Securities Corporation Massachusetts4
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- Kymera Therapeutics, Inc.Jun 22, 2020 to Oct 1, 20263
Timeline
- Aug 5, 20268-K Results of operations37
- Jul 27, 20268-K Executive or director change; Regulation FD disclosure38
- Jun 25, 20268-K Regulation FD disclosure; Other events39
- Jun 24, 20268-K Shareholder vote40
- Jun 8, 20268-K Executive or director change41
- Apr 30, 20268-K Results of operations42
- Mar 27, 20268-K Bylaws or fiscal year changed43
- Feb 26, 20268-K Results of operations44
- Feb 26, 20268-K Entered a material agreement; Ended a material agreement; Other events45
- Jan 13, 20268-K Results of operations; Regulation FD disclosure46
- Dec 10, 20258-K Entered a material agreement; Other events47
- Dec 8, 20258-K Regulation FD disclosure; Other events48
- Aug 21, 2020Went public Listed on NASDAQ1
- Aug 20, 2020New chief executive Nello Mainolfi becomes CEO14
Calendar
Coming up
- Nov 3, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.90) a share, on Nov 4, 2025.49
When it reported results
- Aug 5, 2026Reported quarterly or annual results37
- Apr 30, 2026Reported quarterly or annual results42
- Feb 26, 2026Reported quarterly or annual results44
- Jan 13, 2026Reported quarterly or annual results46
- Nov 4, 2025Reported quarterly or annual results50
- Aug 11, 2025Reported quarterly or annual results51
- May 9, 2025Reported quarterly or annual results52
- Feb 27, 2025Reported quarterly or annual results53
Drug trials and FDA: coming up
- Jun 2027Phase 2 trial readout expected Phase 2 trial of KT-621 in Atopic Dermatitis: primary completion expected Jun 2027 (ClinicalTrials.gov NCT07217015).54
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar
Filings
506 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 63 major events, 211 insider forms, 59 large holders, 153 other. The latest 20:
- Oct 1, 2026144 EDGAR
- Oct 1, 20264 EDGAR
- Sep 8, 2026SCHEDULE 13G/A EDGAR
- Sep 4, 20264 EDGAR
- Sep 4, 2026144 EDGAR
- Sep 2, 2026144 EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 13, 2026SCHEDULE 13G/A EDGAR
- Aug 5, 202610-Q EDGAR
- Aug 5, 20268-K EDGAR
- Jul 27, 20264 EDGAR
- Jul 27, 20263 EDGAR
- Jul 27, 20268-K EDGAR
- Jul 7, 2026144 EDGAR
- Jul 7, 20264 EDGAR
- Jul 2, 2026144 EDGAR
- Jul 2, 20264/A EDGAR
- Jul 2, 20264 EDGAR
- Jul 2, 20264 EDGAR
- Jul 2, 20264 EDGAR
The 506 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
149 open-market trades by officers, directors and large owners since October 2021: 17 buys and 132 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 4, 2026 | Adams BrianChief Legal Officer | Sale | 6,371 | $116.83 | $744.3K | Form 4 |
| Jul 7, 2026 | Mainolfi NelloChief Executive Officer | Sale | 50,000 | $119.00 | $6.0M | Form 4 |
| Jul 1, 2026 | Goodman NoahChief Business Officer | Sale | 3,389 | $114.29 | $387.3K | Form 4 |
| Jul 1, 2026 | Mainolfi NelloChief Executive Officer | Sale | 80,000 | $115.30 | $9.2M | Form 4 |
| Jun 30, 2026 | Jacobs Bruce N.Chief Financial Officer | Sale | 77,109 | $114.97 | $8.9M | Form 4 |
| Jun 29, 2026 | Booth BruceDirector | Sale | 76,650 | $108.05 | $8.3M | Form 4 |
| Jun 29, 2026 | Booth BruceDirector | Sale | 31,283 | $109.48 | $3.4M | Form 4 |
| Jun 29, 2026 | Booth BruceDirector | Sale | 45,367 | $107.06 | $4.9M | Form 4 |
| Jun 26, 2026 | Booth BruceDirector | Sale | 467,878 | $110.29 | $51.6M | Form 4 |
| Jun 26, 2026 | BIOTECHNOLOGY VALUE FUND II LPDirector | Sale | 1,630,658 | $106.50 | $173.7M | Form 4 |
| Jun 25, 2026 | Booth BruceDirector | Sale | 285,684 | $121.86 | $34.8M | Form 4 |
| Jun 25, 2026 | Booth BruceDirector | Sale | 262,637 | $115.39 | $30.3M | Form 4 |
| Jun 25, 2026 | Goodman NoahChief Business Officer | Sale | 5,000 | $114.00 | $570.0K | Form 4 |
| Jun 24, 2026 | Booth BruceDirector | Sale | 134,720 | $100.51 | $13.5M | Form 4 |
| Jun 23, 2026 | Booth BruceDirector | Sale | 1,408 | $99.98 | $140.8K | Form 4 |
| Jun 22, 2026 | Booth BruceDirector | Sale | 31,798 | $103.75 | $3.3M | Form 4 |
| Jun 22, 2026 | Booth BruceDirector | Sale | 246,330 | $98.52 | $24.3M | Form 4 |
| Jun 22, 2026 | Goodman NoahChief Business Officer | Sale | 2,500 | $99.00 | $247.5K | Form 4 |
| Jun 18, 2026 | Booth BruceDirector | Sale | 115,056 | $91.01 | $10.5M | Form 4 |
| Jun 17, 2026 | Booth BruceDirector | Sale | 116,812 | $90.34 | $10.6M | Form 4 |
All 149 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- PRICE T ROWE ASSOCIATES INC /MD/SCHEDULE 13G/A, 9 filings Feb 14, 2022 to Sep 8, 202655
- Atlas Venture Fund X, L.P.SCHEDULE 13G/A, 5 filings Feb 11, 2022 to Aug 13, 202656
- BIOTECHNOLOGY VALUE FUND L PSCHEDULE 13D/A, 6 filings Jan 31, 2022 to Jun 26, 202657
- T. Rowe Price Investment Management, Inc.SCHEDULE 13G, 1 filing May 15, 202658
- Wellington Management CompanySCHEDULE 13G/A, 9 filings Feb 4, 2022 to May 15, 202659
- FMR LLCSCHEDULE 13G/A, 6 filings Feb 9, 2022 to May 6, 202660
- VANGUARD GROUP INCSCHEDULE 13G/A, 5 filings Feb 10, 2022 to Mar 27, 202661
- BAKER BROS. ADVISORS LPSCHEDULE 13D/A, 6 filings Feb 14, 2023 to Dec 11, 202562
- BlackRockSCHEDULE 13G/A, 4 filings Feb 4, 2022 to Jul 17, 202563
- Avoro Capital Advisors LLCSC 13G/A, 3 filings Feb 14, 2023 to Nov 14, 202464
- State Street CorporationSC 13G/A, 2 filings Feb 8, 2023 to Jan 23, 202465
- Vertex PharmaceuticalsSC 13D/A, 1 filing Jun 5, 202366
- Redmile Group, LLCSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202367
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Nello MainolfiPh.D. | $693.0K | $8.5M68 | |
| 2025 | Brian AdamsJ.D. | 52 | $145.2K | $6.1M68 |
| 2025 | Noah GoodmanMBA | $294.0K | $3.2M68 | |
| 2025 | Jared GollobM.D. | 62 | $507.1K | $2.9M68 |
| 2025 | Bruce JacobsCFA, MBA | $500.0K | $2.9M68 | |
| 2024 | FounderPresident and | $670.0K | $15.4M68 | |
| 2024 | Chief Financial Officer | $481.0K | $7.1M68 | |
| 2024 | Chief Medical Officer | $490.0K | $5.7M68 | |
| 2023 | Chief Executive Officer | $640.0K | $9.7M68 | |
| 2023 | Chief Financial Officer | $470.0K | $4.2M68 | |
| 2023 | Chief Medical Officer | $480.0K | $3.5M68 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Fmr LLC | 12,349,256 | $1.4B | 0.1% | +649,306 |
| Baker Bros. Advisors LP | 8,657,242 | $992.7M | 5.0% | No change |
| Avoro Capital Advisors LLC | 7,474,747 | $857.1M | 7.7% | No change |
| BlackRock, Inc. | 5,538,210 | $635.1M | 0.0% | +477,334 |
| Bvf Inc/il | 3,872,052 | $444.0M | 11.4% | −1,630,658 |
| Wellington Management Group Llp | 3,675,028 | $421.4M | 0.1% | −214,659 |
| Vanguard Portfolio Management LLC | 2,992,193 | $343.1M | 0.0% | +118,137 |
| Siren, L.L.C. | 2,935,830 | $336.7M | 6.8% | −251,000 |
| Vanguard Capital Management LLC | 2,932,378 | $336.3M | 0.0% | +52,054 |
| Atlas Venture Life Science Advisors, LLC | 2,847,541 | $326.5M | 37.1% | −1,730,467 |
| State Street Corp | 2,737,226 | $313.9M | 0.0% | +347,459 |
| Geode Capital Management, LLC | 1,816,331 | $208.3M | 0.0% | +170,981 |
| Capital Research Global Investors | 1,388,881 | $159.3M | 0.0% | −284,394 |
| Goldman Sachs Group Inc | 1,187,333 | $136.2M | 0.0% | +298,924 |
| UBS Group AG | 1,007,777 | $115.6M | 0.0% | −16,075 |
| Driehaus Capital Management LLC | 919,233 | $105.4M | 0.6% | −124,350 |
| Merck & Co., Inc. | 772,165 | $88.5M | 16.8% | No change |
| Norges Bank | 757,246 | $86.8M | 0.0% | New |
| Federated Hermes, Inc. | 749,398 | $85.9M | 0.1% | +212,718 |
| Dimensional Fund Advisors LP | 745,152 | $85.4M | 0.0% | +152,273 |
| Frontier Capital Management Co LLC | 740,866 | $85.0M | 0.8% | −18,982 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 736,866 | $84.5M | 0.0% | −139,006 |
| Alliancebernstein L.P. | 981,521 | $81.8M | 0.0% | +93,486 |
| Holocene Advisors, LP | 636,579 | $73.0M | 0.2% | −200,180 |
| Northern Trust Corp | 581,907 | $66.7M | 0.0% | +87,468 |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Kymera Therapeutics is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARKymera Therapeutics, Inc.2
- CIK0001815442
- Employer ID (EIN)81-29921665
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company5
- Incorporated inDelaware5
- Fiscal year endsDecember 312
- Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)2
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
- Business address500 North Beacon Street, 4Th Floor, Watertown, MA 024722
- Phone857-285-53142
- Shares outstanding83,150,618 as of Jul 31, 202612
- Public float$2.3B as of Dec 31, 20255
- AuditorErnst & Young LLP, Boston, Massachusetts PCAOB ID 42; it also attests to the company’s internal control over financial reporting5
- On EDGAR sinceJun 22, 20202
- Filings644 in all: 4 (265), 144 (118), 8-K (76), 3 (28), SC 13G/A (23), 10-Q (18), SCHEDULE 13G/A (16), SC 13G (11)2
All 32 form types
424B5 (9), CORRESP (8), S-8 (7), 10-K (6), DEF 14A (6), DEFA14A (6), SC 13D/A (6), UPLOAD (5), ARS (4), SCHEDULE 13D/A (4), 4/A (3), S-1/A (3), SC 13D (3), 424B3 (2), 424B4 (2), DRS (2), EFFECT (2), S-1 (2), S-1MEF (2), S-3ASR (2), SEC STAFF LETTER (2), 8-A12B (1), CERT (1), SCHEDULE 13G (1)
- Latest filingsAnnual report (10-K) Feb 26, 2026
Quarterly report (10-Q) Aug 5, 2026
Proxy statement (DEF 14A) Apr 29, 2026
Latest 8-K (8-K) Aug 5, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, par value $0.0001 per share | KYMR | The Nasdaq Global Market |
From the cover page of the 10-K filed Feb 26, 2026 (Section 12(b) of the Exchange Act).5
Risk factors and legal proceedings
The risks Kymera Therapeutics names in Item 1A of its 10-K filed Feb 26, 2026: 71 risks under these headings, as written.5
- Risks Related to Our Financial Position and Need for Additional Capital
- We are a clinical stage company and that may make it difficult for our stockholders to evaluate the success of our business to date and to assess our future viability.
- We have incurred significant operating losses since our inception and anticipate that we will incur continued losses for the foreseeable future.
- We will need to raise substantial additional funding. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, scale back or discontinue some of our product candidate development programs or future commercialization efforts.
- Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.
- We will continue to incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.
- Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults, or non-performance by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and our financial condition and results of operations.
- Risks Related to Drug Development and Regulatory Approval
- We are very early in our development efforts and our STAT6 and IRF5 programs are in early clinical development with additional programs in preclinical development. If we are unable to advance our programs into and through the clinic for safety or efficacy reasons or commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.
- Our approach to the discovery and development of product candidates is novel and unproven, which makes it difficult to predict the time, cost of development and likelihood of successfully developing any products.
- We may not be successful in our efforts to identify or discover additional product candidates or we may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
- We depend heavily on the successful development of our lead programs. We cannot be certain that we will be able to obtain regulatory approval for, or successfully commercialize, any of our current or future product candidates.
The other 61 risks
- If we experience delays or difficulties in the initiation or enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.
- Interim, “topline,” and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
- Positive results from early preclinical studies and clinical trials of our current or future product candidates are not necessarily predictive of the results of later preclinical studies and clinical trials of our current or future product candidates. If we cannot replicate the positive results from our preclinical studies of our current or future product candidates in our future clinical trials, we may be unable to successfully develop, obtain regulatory approval for and commercialize our current or future product candidates.
- The incidence and prevalence for target patient populations of our product candidates have not been established with precision. If the market opportunities for our product candidates are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability will be adversely affected, possibly materially.
- A pandemic, epidemic, or outbreak of an infectious disease may materially and adversely affect our business and our financial results and could cause a disruption to the development of our product candidates.
- Our current or future product candidates may cause adverse or other undesirable side effects that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.
- Manufacturing our current or future product candidates is complex and we may encounter difficulties in production. If we encounter such difficulties, our ability to provide supply of our current or future product candidates for preclinical studies and clinical trials or for commercial purposes could be delayed or stopped.
- If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our current or future product candidates, we will not be able to commercialize, or will be delayed in commercializing, our current or future product candidates, and our ability to generate revenue will be materially impaired.
- We may seek Breakthrough Therapy Designation and/or Fast Track Designation for any of our current or future product candidates. These designations, even if granted by the FDA, may not lead to a faster development, regulatory review or approval process, and such designations do not increase the likelihood that any of our product candidates will receive marketing approval in the United States.
- We or our collaborators may seek approval of KT-621, KT-579 or any other future product candidate, where applicable, under the FDA’s accelerated approval pathway. This pathway may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.
- We may seek Orphan Drug Designation for certain of our current or future product candidates, and we may be unsuccessful or may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential for market exclusivity.
- Even if we receive regulatory approval for any of our current or future product candidates, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, our current or future product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates when and if any of them are approved.
- Even if we receive marketing approval for our current or future product candidates in the U.S., we may never receive regulatory approval to market our current or future product candidates outside of the U.S.
- Our future growth may depend, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties that could materially adversely affect our business.
- We may in the future conduct clinical trials for current or future product candidates outside the U.S., and the FDA and comparable foreign regulatory authorities may not accept data from such trials.
- We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations.
- Governments outside the United States tend to impose strict price controls, which may adversely affect our revenues, if any.
- Even if we are able to commercialize any current or future product candidates, such drugs may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business.
- Current and future healthcare legislative reform measures may have a material adverse effect on our business and results of operations.
- Our relationships with customers, health care providers, physicians, and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual damages, reputational harm and diminished future profits and earnings.
- If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.
- Our employees, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading laws.
- Risks Related to Commercialization
- Even if we receive marketing approval for our current or future product candidates, our current or future product candidates may not achieve broad market acceptance, which would limit the revenue that we generate from their sales.
- We face substantial competition, which may result in others discovering, developing or commercializing drugs before or more successfully than we do.
- Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any current or future product candidates that we may develop.
- If, in the future, we are unable to establish sales and marketing and patient support capabilities or enter into agreements with third parties to sell and market our current or future product candidates, we may not be successful in commercializing our current or future product candidates if and when they are approved, and we may not be able to generate any revenue.
- Risks Related to Our Dependence on Third Parties
- We rely, and expect to continue to rely, on third parties to conduct our ongoing and planned preclinical studies and clinical trials for our current and future product candidates. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain marketing approval for or commercialize our current and potential future product candidates and our business could be substantially harmed.
- The third parties upon whom we rely for the supply of the API, drug product, and starting materials used in our product candidates are limited in number, and the loss of any of these suppliers could significantly harm our business.
- We may depend on collaborations with other third parties for the development and commercialization of our product candidates in the future. If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.
- Our manufacturing process needs to comply with FDA regulations relating to the quality and reliability of such processes. Any failure to comply with relevant regulations could result in delays in or termination of our preclinical and clinical programs and suspension or withdrawal of any regulatory approvals.
- If our third-party manufacturers use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages.
- Risks Related to Intellectual Property
- If we are unable to obtain and maintain patent and other intellectual property protection for our technology and product candidates or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and drugs similar or identical to ours, and our ability to successfully commercialize our technology and drugs may be impaired, and we may not be able to compete effectively in our market.
- If we fail to comply with our obligations in our current or any future agreements under which we may license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.
- Intellectual property rights do not guarantee commercial success of current or future product candidates or other business activities. Numerous factors may limit any potential competitive advantage provided by our intellectual property rights.
- Obtaining and maintaining our patent protection, including patent term, depends on compliance with various procedural, document submission, deadlines, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated if we miss a filing deadline for patent protection on these inventions or otherwise fail to comply with these requirements.
- Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our current or future product candidates.
- If our trademarks for our products or company name are not adequately protected in one or more countries where we intend to market our products, we may delay the launch of product brand names, use different or less effective trademarks or tradenames in different countries, or face other potentially adverse consequences or impediments to building our product brand recognition.
- If we are unable to adequately protect and enforce our trade secrets, our business and competitive position would be harmed.
- We may initiate, become a defendant in, or otherwise become party to lawsuits to protect or enforce our intellectual property rights, which could be expensive, time-consuming and unsuccessful.
- We may be subject to damages or settlement costs resulting from claims that we or our employees have violated the intellectual property rights of third parties, or are in breach of our agreements. We may be accused of, allege or otherwise become party to lawsuits or disputes alleging wrongful disclosure of third-party confidential information by us or by another party, including current or former employees, contractors or consultants. In addition to diverting attention and resources, such disputes could adversely impact our business reputation and/or protection of our proprietary technology.
- We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might subject us to infringement claims or adversely affect our ability to develop and market our current or future product candidates.
- Risks Related to Employee Matters, Managing Growth and Other Risks Related to Our Business
- Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.
- We will need to continue to develop and expand our company, and we may encounter difficulties in managing this development and expansion, which could disrupt our operations.
- We or the third parties upon whom we depend may be adversely affected by unforeseen global events, natural disasters, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.
- We intend to sublease our former space in Watertown, Massachusetts for occupancy now that we have moved to our new facility. If we are unable to sublease our space on favorable terms or if our subtenants are unable to meet their obligations under any sublease, we may be responsible for unexpected costs, which could impact our financial performance.
- Our internal computer systems, or those of our third-party CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our current or future product candidates’ development programs.
- We may be unable to adequately protect our information systems from cyberattacks, security incidents, or compromises, which could result in the disclosure of confidential or proprietary information, including personal data, damage our reputation, and subject us to significant financial and legal exposure.
- We, our collaborators and our service providers may be subject to a variety of privacy and data protection laws, regulations and contractual obligations, which may require us to incur substantial compliance costs, and any failure or perceived failure by us to comply with them could expose us to fines or other penalties and otherwise harm our business and operations.
- Issues relating to the use of artificial intelligence and machine learning could adversely affect our business and operating results.
- Risks Related to Our Common Stock
- The price of our common stock has been and may continue to be volatile and fluctuate substantially, and investors may lose all or part of their investment.
- Unstable global economic and geopolitical conditions may have serious adverse consequences on our business, financial condition, stock price and results of operations.
- If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.
- Our executive officers, directors, principal stockholders and their affiliates exercise significant influence over our company, which will limit your ability to influence corporate matters and could delay or prevent a change in corporate control.
- We have issued a substantial number of warrants and equity awards from our equity plans which are exercisable into shares of our common stock which could result in substantial dilution to the ownership interests of our existing stockholders.
- Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.
- Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be investors’ sole source of gain.
- We may be at an increased risk of securities class action litigation.
- Risks Related to Tax
- Changes in tax law may adversely affect us or our investors.
- Our ability to utilize our net operating loss carryforwards and certain other tax attributes to offset future taxable income may be subject to certain limitations, and, as a result, unavailable to reduce our future tax liability.
- Risks Related to Our Controls and Reporting Requirements
- If we fail to maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed.
- Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
Legal proceedings
From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors.
The opening of Item 3, Legal Proceedings.5
Links
- Websitewww.kymeratx.com1
- WikidataQ113503520
- SEC EDGARCIK 1815442
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataKymera Therapeutics on Wikidata
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18SEC EDGARNoah Goodman, Chief Business Officer
- 19
- 20SEC EDGARJared Gollob, Chief Medical Officer
- 21
- 22SEC EDGARFelix Baker, Board member
- 23SEC EDGARMark N. Lampert, Board member
- 24SEC EDGARJohn Maraganore, Board member
- 25SEC EDGARLeigh Morgan, Board member
- 26SEC EDGARVictor Sandor, Board member
- 27SEC EDGARElena Ridloff, Board member
- 28SEC EDGARAndrew Hedin, Board member
- 29SEC EDGARBruce Booth, Board member
- 30SEC EDGARGorjan Hrustanovic, Board member
- 31SEC EDGARJeffrey W. Albers, Board member
- 32SEC EDGARJoanna Horobin, Board member
- 33SEC EDGARSteven Edward Hall, Board member
- 34SEC EDGARPamela Esposito, Board member
- 35SEC EDGARBrian Adams, General counsel
- 36SEC EDGAREllen Chiniara, General counsel
- 37SEC EDGARResults of operations
- 38
- 39
- 40SEC EDGARShareholder vote
- 41SEC EDGARExecutive or director change
- 42SEC EDGARResults of operations
- 43SEC EDGARBylaws or fiscal year changed
- 44SEC EDGARResults of operations
- 45
- 46
- 47
- 48
- 49NasdaqNasdaq calendar
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68